Samsung Biologics, the biotechnology division of the Samsung Group, announced today that it has partnered with Eli Lilly and Co., a leading US pharmaceutical company, to establish a cutting-edge biotech incubator in Incheon, South Korea.
The collaborative agreement will see the creation of a new Lilly Gateway Labs site in Songdo, a prominent international business district within the port city of Incheon. This initiative aims to foster innovation and growth within the biotech sector.
Lilly Gateway Labs, established by Eli Lilly in 2019, is designed to empower emerging biotech companies. It provides access to state-of-the-art facilities and equipment, financial resources, investment opportunities, and collaborative research and development programs.
